Dr. Chainarong Limvarapuss, MD

Dr. Limvarapuss practices at Solano Hematology - Oncology in Vallejo, California.

Dr. Limvarapuss' NPI, 1053341784, was assigned on July 5, 2006. Dr. Limvarapuss graduated from Siriraj Medical School/Mahidol University in 1989. Dr. Limvarapuss holds California license A80619.

Dr. Limvarapuss' primary practice is Solano Hematology - Oncology, at 100 Hospital Dr, Vallejo, CA 94589 in Solano County. The practice phone is (707) 551-3300.

Dr. Limvarapuss' primary practice is Solano Hematology - Oncology in Vallejo, California. Dr. Limvarapuss is also affiliated with Sutter Solano Medical Center. The medical group on file is Solano Hematology Oncology. Dmand AI also links Dr. Limvarapuss to 1 more hospital, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Limvarapuss practices, 4 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Limvarapuss' primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Limvarapuss is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Limvarapuss' licenses on file in 6 states: California, Florida, Tennessee, Virginia, Illinois and South Carolina.

Dmand AI lists anemia, breast cancer, chronic anemia, chronic embolism thrombosis, chronic leukemia, colorectal cancer, deep vein thrombosis (DVT) and fluid and electrolyte imbalances among the conditions Dr. Limvarapuss treats.

CMS data shows 92,356 Medicare services from Dr. Limvarapuss across 68 procedure codes in 2024, for 370 Medicare patients. Medicare paid $1,269,444 for them.

CMS counts 370 Medicare patients who saw Dr. Limvarapuss in 2024. The largest group is 65 to 74, with 152 patients. 75% of them have high blood pressure, and 70% have high cholesterol. 55% are also on Medicaid. Their average risk score is 1.95, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Limvarapuss' median patient age at 70, with 60% women.

In 2024, Dr. Limvarapuss wrote 3,492 Medicare Part D claims for 299 patients. 77% of them were for generic drugs. CMS names the drug for 2,915 of them, across 91 drugs with 11 or more claims each, at $4,444,561 in total drug cost. In 2023, CMS named 2,907 claims across 95 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Limvarapuss for performance year 2024, reported as part of a group. Dr. Limvarapuss accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Limvarapuss as offering telehealth.

Dmand AI links 5 papers to Dr. Limvarapuss in 2018. 2018 was the busiest year, with 2. The most frequent topics are Apoptosis, Cell Division and Disease Models, Animal. Dr. Limvarapuss has published most often in Int J Oncol. Dr. Limvarapuss' most frequent co-authors are Ayad M. Al-Katib, MD, Mark G. Frattini, MD and John S. Hrom, MD.

Dmand AI links Dr. Limvarapuss to 2 clinical trials. 2 are still active or recruiting. Conditions studied include Lymphoma, Large B-Cell, Diffuse, Medulloblastoma and Lymphoma, B-Cell.

CMS Open Payments shows 1,973 general payments to Dr. Limvarapuss from 97 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 49% of the total. Novartis Pharmaceuticals Corporation paid the most, $12,859. It also lists 1 research payment totaling $22,505 in 2016.

Dmand AI lists 1 award for Dr. Limvarapuss, most recently CMS Stage 1 2012 in 2011.

Dr. Limvarapuss graduated from Siriraj Medical School/Mahidol University in 1989. Dr. Limvarapuss is a member of ACP.

Dr. Limvarapuss is in network with 14 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 10. Check the plan with the practice before a visit.